Thursday 24th July, Cambridge, UK – Camgenium today announced its partnership with Professor Petre Cristian Ilie, Consultant Urological and Robotic Surgeon at NNUH NHS Foundation Trust, to develop HealthiumPro, a cloud-based innovative software solution. The system has the potential to improve the outcomes of prostate cancer patients by enhancing safety before and after surgery.
Prostate cancer is the most commonly diagnosed cancer in men in the UK, with 55,000 cases diagnosed annually. Its rate of incidence is expected to increase by 15% between 2023 and 2040.i,ii Many men with prostate…
Sandwich, UK (22 July 2025) – Discovery Park based Logical Biological – biospecimen and critical material experts – today announced the launch of a new sister company, Logical Antigen. The new company focuses on rapid and customised delivery of high-quality antigens and biologicals for research and manufacturing of diagnostic products.
Antigens are a key component in the manufacture of in vitro diagnostic (IVD) test reagents, often used in controls to confirm test performance. However, unmet needs currently exist in relation to protein derived material availability, suitability and consistent…
In the second quarter of 2025 Coulter Partners drove global executive search for a wide range of life sciences, health, and technology organizations. We successfully placed executives for venture capital & private equity-backed firms, alongside large-cap, mid-cap, and public companies, filling critical roles across diverse disciplines worldwide.CEO/ C-suite/ BoardCEO, ADC oncology company (VC-backed), UKCEO, Immuno-oncology therapeutics (Publicly listed), USCEO, Sustainable chemical biomanufacturing (VC-backed), SwedenCEO, Exosome technologies (VC-backed), ItalyChief Commercial…
Breakthrough data validates capabilities of GlueSEEKER platform to identify novel induced protein-protein interactions and expand druggable space
Cambridge, UK, 22 July 2025: PhoreMost Ltd., a next-generation targeted protein degradation (TPD) company progressing a pipeline of degrader therapeutics within oncology and inflammation, today announced the publication of a study demonstrating the capabilities of its high-throughput GlueSEEKER platform to accelerate the design and development of novel molecular glue degraders1.
The paper, titled “Systematic molecular glue drug discovery with a high…
Pioneer Group and Science Creates today announce a new partnership that will support the next generation of science and technology ventures across the UK and Ireland.
The collaboration brings together two mission-led organisations committed to helping founders translate scientific discovery into commercial solutions to tackle some of the most pressing challenges in human and planetary health.
Together, Pioneer and Science Creates have supported over 350 innovation-driven startups and spinouts with specialist lab and office space, investment, training programmes and access to expertise and…
GenePORTER® Gold from Amsbio is a highly reproducible, lipid-based gene transfection reagent delivering exceptional efficiency across the widest range of cell lines. Utilizing proprietary Advanced Carrier Enhancement (ACE) technology - GenePORTER® Gold delivers outstanding transfection efficiency and transgene expression levels with minimal cytotoxicity.
The transfection efficiency levels achieved with GenePORTER Gold match or surpass other commercially available transfection reagents. The GenePORTER Gold kit includes an easy-to-use protocol and enough reagent for 400 x 1 microgram…
Amsbio offers a wide range of highly pure, lyophilized exosome standards designed to support reproducibility and standardization in extracellular vesicle (EV) research.Exosomes are small lipid nanoparticles actively secreted by exocytosis in most living cells. Regulating pleiotropic physiological and pathological functions – exosomes have been shown to play significant roles in diverse pathological conditions such as cancer, infectious and neurodegenerative diseases. Currently there is growing interest in exosomes as promising new tools for use such as biomarkers and therapeutics.The…
Two groundbreaking drug discovery projects, supported by Medicines Discovery Catapult (MDC), have secured over £1m in funding from Innovate UK's Launchpad Northern Ireland programme.
SignaCor Therapeutics and Klas Therapeutics, both based in Northern Ireland, have been awarded a share of funding from the Launchpad programme.
The funding provides a vital boost to the SMEs' research programmes, which focus on innovations to treat heart disease and skin cancer.
MDC, a national Life Science service dedicated to supporting drug discovery teams to develop marketed therapies, will…
Engineered and humanized antibodies are now taking charge of the driving force behind a new era in drug discovery, from breakthrough cancer treatments to next-gen biologics.The Antibody Revolution: Precision Weapons Against CancerAs highlighted in industry main news channels Trends in Biotechnology and SciTechDaily, recombinant antibodies—customized for enhanced potency and accuracy—are making tidal waves in the immunotherapy space. But while demand skyrockets, high-quality antibody reagents remain notoriously hard to come by.Creative Biolabs, enthusiastically coming in to AI-driven antibody…
LONDON, UK, and MELBOURNE, Australia, July 15, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for QBiotics Group Limited (QBiotics) and is pleased to announce the placement of Sergio Duchini as Non-executive Director.QBiotics is an unlisted public Australian life sciences company that specializes in the discovery and development of novel small molecules to treat complex medical conditions. Its current therapeutic focus is on oncology and wound healing. The…